Psychedelic Brain Science

It's been 3 years since the last microdosing review...and 20+ papers have come out since making it necessary to revisit the microdosing scientific literature and check-in with Dr. Jaster. Is she still a microdosing skeptic? Listen to this rapid fire breakdown of some the key themes from the microdosing literature and follow along by accessing the papers in the link below:https://drive.google.com/drive/folders/1QB3CMUrbern3tgS5QPp6tZ9ixNmq5_0X?usp=sharing

Dr. Jaster attended the FDA hearing on "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," and sat down only hours after to give you her unfiltered thoughts. The hearing took place on September 14, 2026 from 12:30 to 4:30ET. There were two sessions of public comments that featured approximately 80 speakers. The first session focused on provider training, credentialing and patient safety. The second session was focused on access, data collection and standardization.While the hearing is over, the written public comment period is open until 11:59 ET on October 5th. To submit, visit https://www.federalregister.gov/documents/2026/07/14/2026-14155/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-hearing-request-for

Psychedelic policy is moving faster than most people realize - and the next 12 months could decide which therapies reach patients first. On the Season 6 premiere of Psychedelic Brain Science, Dr. Alaina Jaster is joined by Josh Hardman, Founder of Psychedelic Alpha. Together they break down the regulatory sprint, the companies closest to the finish line, and why "approval" may not mean access as quickly as you think.They also get into the broader policy picture: where decriminalization appears to be slowing, how medicalized models are taking hold why the psychedelics conversation is increasingly about more than one pathway, including the growing role of non-hallucinogenic neuroplastogens. To learn more and explore the various trackers at Psychedelic Alpha visit: https://psychedelicalpha.com/

In this episode, Dr. J is joined by Dr. Leah Salinsky, a postdoctoral researcher at University of Washington. They discuss the role of serotonin in addiction, the importance of drug discrimination models, and the unique interactions between psychedelics and opioids. Leah shares insights from her current research on polysubstance use, some unpublished findings, and the potential of psychedelics to reverse social deficits associated with substance use disorders.For her recent publications discussed in this episode:https://drive.google.com/drive/folders/12OI64pebeQ8Hj2zhxn-zdPj1DEAVZSJS?usp=sharing

In this episode of Psychedelic Brain Science, Dr. J is joined by Victoria Cvitanovic, a lawyer at Rudick Law Group with a focus on psychedelic medicine, cannabis and healthcare. Throughout the episode they discuss the evolving landscape of drug policy with an emphasis on the importance of understanding the consequences of drug laws on individuals and communities. Victoria also shares her own experiences as a prosecutor, lawyer, and someone with a disability, and how that has shaped her own practice and advocacy. Check out links below for more resources!Rudick Law Group: https://www.rudicklawgroup.com/National Bail Fund: https://www.communityjusticeexchange.org/en/nbfn-directoryResources on Disability Justice:https://transgenderlawcenter.org/programs/disability-project/Resources on scientific advocacy: https://www.psychedelicbrainscience.com/post/so-you-want-to-be-an-advocate